Technical Analysis for FTSV - Forty Seven, Inc.

Grade Last Price % Change Price Change
grade F 7.63 1.87% 0.14
FTSV closed up 1.87 percent on Friday, September 20, 2019, on 1.99 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FTSV trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
20 DMA Support Bullish 1.87%
NR7 Range Contraction 1.87%
NR7-2 Range Contraction 1.87%
20 DMA Support Bullish 1.87%
NR7 Range Contraction 1.87%
Down 3 Days in a Row Weakness 1.87%
Inside Day Range Contraction -2.68%
Stochastic Sell Signal Bearish -4.27%

Older signals for FTSV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
Medicine Cancer Medical Specialties Immunology Cancers Monoclonal Antibodies Cancer Immunotherapy Ovarian Cancer Lymphoma Acute Myeloid Leukemia Cancer Research Humanized Antibody NHL CD47
Is FTSV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.83
52 Week Low 6.04
Average Volume 297,704
200-Day Moving Average 13.5224
50-Day Moving Average 8.0284
20-Day Moving Average 7.4755
10-Day Moving Average 7.757
Average True Range 0.4565
ADX 18.09
+DI 23.5287
-DI 19.4418
Chandelier Exit (Long, 3 ATRs ) 6.9704
Chandelier Exit (Short, 3 ATRs ) 7.9895
Upper Bollinger Band 8.2328
Lower Bollinger Band 6.7182
Percent B (%b) 0.6
BandWidth 20.260852
MACD Line -0.0798
MACD Signal Line -0.1403
MACD Histogram 0.0605
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.31
Resistance 3 (R3) 8.33 8.13 8.20
Resistance 2 (R2) 8.13 7.95 8.12 8.16
Resistance 1 (R1) 7.88 7.85 8.00 7.86 8.12
Pivot Point 7.67 7.67 7.73 7.66 7.67
Support 1 (S1) 7.42 7.50 7.55 7.40 7.14
Support 2 (S2) 7.22 7.39 7.21 7.10
Support 3 (S3) 6.97 7.22 7.06
Support 4 (S4) 6.95